DZ Bank AG reissued their neutral rating on shares of Merck KGaA (FRA:MRK) in a research note published on Tuesday.

Other equities research analysts have also issued research reports about the stock. Kepler Capital Markets set a €119.00 ($138.37) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Monday, July 31st. S&P Global set a €110.00 ($127.91) target price on shares of Merck KGaA and gave the company a buy rating in a research note on Thursday, August 3rd. equinet AG set a €112.00 ($130.23) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Thursday, August 31st. BNP Paribas set a €116.00 ($134.88) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Wednesday, September 6th. Finally, Warburg Research set a €115.00 ($133.72) price objective on shares of Merck KGaA and gave the stock a buy rating in a research note on Wednesday, September 6th. Eleven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of €109.00 ($126.74).

Merck KGaA (FRA MRK) opened at €91.04 ($105.86) on Tuesday. Merck KGaA has a 1 year low of €89.21 ($103.73) and a 1 year high of €115.00 ($133.72).

ILLEGAL ACTIVITY WARNING: “Merck KGaA’s (MRK) “Neutral” Rating Reiterated at DZ Bank AG” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://theolympiareport.com/2017/11/17/merck-kgaas-mrk-neutral-rating-reiterated-at-dz-bank-ag.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.